{"entity":{"id":"idea-tr2-termination-reports","kind":"idea","name":"Public post-mortem reports when a cancer drug programme is stopped","aka":[],"tldr":"When an aeroplane crashes, an independent report explains why so it does not happen again. When a cancer drug programme is abandoned, nothing is written. Change that.","summary":"Programme discontinuations are announced in earnings calls with a sentence. A structured termination report (target and mechanism, models used, what was predicted versus observed in humans, pharmacokinetics achieved, toxicities, the decision rationale, and lessons) published within twelve months of discontinuation, under a standard template, would turn each failure into shared learning. Precedents: aviation safety reporting, and the few published examples such as the analysis of the anti-CD47 and Rova-T programmes.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)","url":"https://doi.org/10.1056/NEJMsa1409364"}],"tags":[],"related":["idea-tr2-failure-taxonomy"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["rovalpituzumab-tesirine","magrolimab","epacadostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-negative-results","b-knowledge-diffusion"],"keyPapers":["paper-anderson-n-engl-j-med"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Regular publication of termination reports will reduce the number of subsequent programmes against the same target with the same failure mode by at least a third, measurable in pipeline databases over five years.","rationale":"Each failure carries information about targets, models and endpoints that the next entrant lacks. Duplicated failures against IDO1, CD47 and DLL3 ADCs show the cost of silence.","test":"Persuade three sponsors to publish reports for their next five discontinued oncology programmes; survey competitors and academics on whether the reports changed decisions.","maturity":"speculative","actor":"industry","cost":"small","horizonYears":2},"route":"/ideas/idea-tr2-termination-reports/","neighbours":{"idea":[{"id":"idea-tr2-shelved-asset-commons","kind":"idea","name":"A commons of shelved cancer drugs with their full data, open to new hypotheses","route":"/ideas/idea-tr2-shelved-asset-commons/"},{"id":"idea-tr2-failure-taxonomy","kind":"idea","name":"A machine-readable taxonomy of why cancer drugs fail","route":"/ideas/idea-tr2-failure-taxonomy/"},{"id":"idea-tr2-material-failure-disclosure","kind":"idea","name":"Listed companies must disclose top-line data, not just 'did not meet endpoint'","route":"/ideas/idea-tr2-material-failure-disclosure/"}],"drug":[{"id":"epacadostat","kind":"drug","name":"Epacadostat","route":"/drugs/epacadostat/"},{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/"},{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/"}],"bottleneck":[{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"}],"paper":[{"id":"paper-anderson-n-engl-j-med","kind":"paper","name":"Compliance with results reporting at ClinicalTrials.gov","route":"/key-papers/paper-anderson-n-engl-j-med/"}]}}